Synthesis, antimicrobial and antiproliferative properties of epi-oligomycin A, the (33S)-diastereomer of oligomycin A. 2020

Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
Gause Institute of New Antibiotics, Moscow, 119021, Russian Federation.

We describe the synthesis of epi-oligomycin A, a (33S)-diastereomer of the antibiotic oligomycin A. The structure of (33S)-oligomycin A was determined by elemental analysis, spectroscopic studies, including 1D and 2D NMR spectroscopy, and mass spectrometry. Isomerization of C33 hydroxyl group led to minor changes in the potency against Aspergillus niger, Candida spp., and filamentous fungi whereas the activity against Streptomyces fradiae decreased by approximately 20-fold compared to oligomycin A. We observed that 33-epi-oligomycin A had the same activity on the human leukemia cell line K562 as oligomycin A but was more potent for the multidrug resistant subline K562/4. Non-malignant cells were less sensitive to both oligomycin isomers. Finally, our results pointed at the dependence of the cytotoxicity of oligomycins on oxygen supply.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D009840 Oligomycins A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X). Oligomycin
D002175 Candida A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; VULVOVAGINAL CANDIDIASIS; and CANDIDIASIS, ORAL (THRUSH). Candida guilliermondii var. nitratophila,Candida utilis,Cyberlindnera jadinii,Hansenula jadinii,Lindnera jadinii,Monilia,Pichia jadinii,Saccharomyces jadinii,Torula utilis,Torulopsis utilis,Monilias
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D001234 Aspergillus niger An imperfect fungus causing smut or black mold of several fruits and vegetables such as grapes, apricots, onions, and peanuts, and is a common contaminant of food. Aspergillus lacticoffeatus

Related Publications

Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
April 2012, The Journal of antibiotics,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
April 2022, Molecules (Basel, Switzerland),
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
March 2016, Carbohydrate research,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
December 1981, The Journal of antibiotics,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
January 2016, Drug design, development and therapy,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
October 2008, Bioorganic & medicinal chemistry letters,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
April 2014, European journal of medicinal chemistry,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
April 2019, Organic letters,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
March 2019, The Journal of organic chemistry,
Lyudmila N Lysenkova, and Oleg Y Saveljev, and Olga A Omelchuk, and George V Zatonsky, and Alexander M Korolev, and Natalya E Grammatikova, and Olga B Bekker, and Valery N Danilenko, and Lyubov G Dezhenkova, and Dilara A Mavletova, and Alexander M Scherbakov, and Andrey E Shchekotikhin
September 2020, Antibiotics (Basel, Switzerland),
Copied contents to your clipboard!